Abstract
Diabetes mellitus (DM) is a well-known risk factor for mortality, and the risk is exacerbated by coexisting diabetic kidney disease (DKD). We aimed to explore the impact of DM on each cause of mortality according to kidney function and the presence of albuminuria. Data on subjects with DM were extracted from the Nationwide Health Insurance Database of South Korea between 2009 and 2012. Subjects were divided by eGFR and albuminuria into five groups. To evaluate the risk of diabetes, we used the Cox proportional hazards model. A total of 2,614,662 patients were enrolled in this study. Most causes of death showed a higher incidence in an advanced stage of DKD. In addition to all-cause mortality and cardiovascular death, the risk of death from neoplasms and diseases of the endocrine, respiratory, and digestive systems is increased by albuminuria. The synergistic effect of a reduced eGFR and the presence of albuminuria was prominent in death from circulatory diseases, and endocrine and metabolic diseases. The risk for mortality was different according to the stage of DKD. Even in patients with a favorable eGFR, the presence of albuminuria significantly increased the risk for mortality, especially that due to cardiovascular causes.
Subject terms: Endocrine system and metabolic diseases, Nephrology
Introduction
Diabetes mellitus (DM) is one of the leading causes of disability and mortality, accounting for approximately 10% of all deaths between the ages of 20 and 79 years1,2. In addition, following the increase in prevalence of diabetes3,4, its disease burden notably increased with diverse aspects of the disease spectrum. As a multisystemic disorder that influences vascular injury with the dysregulation of blood glucose, diabetes significantly contributes to increased mortality5. In particular, the rates of premature mortality from diabetes increased by 5% between 2000 and 20166.
DM is a well-known underlying risk factor for cardiovascular disease, including coronary heart disease, cerebrovascular disease, and peripheral arterial disease7–10. Additionally, it can affect the prognosis of such comorbidities, including malignant disease, cerebrovascular disease, Alzheimer’s disease, respiratory disease, and kidney disease 11–14. Although the pathophysiology is distinguished according to the disease category, diabetes has a common role as an independent risk factor for disease progression. In contrast to the diverse effect of diabetes on other conditions, there is a lack of literature identifying the impact of diabetes on various causes of mortality.
For patients with diabetes, the prognosis varies widely according to the presence of microvascular complications such as diabetic kidney disease (DKD). The presence of albuminuria has usually been regarded as an early marker of kidney damage as well as decreased kidney function, and it is closely linked to poor prognosis in diabetic patients15,16. The significance of albuminuria as a prognostic marker for major cardiovascular disease and mortality has been emphasized17,18. Moreover, albuminuria also has a role in increasing the risk of other systemic diseases, such as pulmonary disease, inflammatory bowel disease, and cerebrovascular disease19–21. However, the impact of albuminuria on each cause of death has not yet been clearly evaluated.
In this study, we aimed to elucidate the risk of each cause of mortality according to the stage of DKD. In addition, we tried to identify the impact of the presence of albuminuria on mortality within each stage of DKD.
Results
Baseline characteristics
Among 2,625,119 patients with diabetes who underwent the national health examination, 2,614,662 patients were ultimately enrolled in this study (Fig. 1). The comparison of baseline characteristics between the groups is shown in Table 1. The average age of the subjects in all groups was 50 years or older, and the proportion of males was higher than that of females, except in group 4. More than 50% of the study participants, except those in group 1, had hypertension. There was a significant difference in the overall demographic findings according to the DKD stage, but it was not stratified according to kidney function. The proportion of subjects with albuminuria increased with decreased kidney function.
Figure 1.
Flow diagram of the study.
Table 1.
Baseline characteristics according to DKD stage.
| aNo DKD (n = 880,927) | bDKD stage 1 (n = 51,406) | cDKD stage 2 (n = 1,384,982) | dDKD stage 3 (n = 257,638) | eDKD stage 4 (n = 39,709) | P value | |
|---|---|---|---|---|---|---|
| Age (years) | 53.18 ± 11.49 | 53.4 ± 11.06 | 58.31 ± 12.12 | 67.2 ± 9.98 | 57.63 ± 13.16 | < 0.0001 |
| 20–29 | 22,776 (2.59) | 999 (1.94) | 11,910 (0.86) | 301 (0.12) | 679 (1.71) | |
| 30–39 | 82,082 (9.32) | 3889 (7.57) | 74,648 (5.39) | 1564 (0.61) | 2927 (7.37) | |
| 40–49 | 197,603 (22.43) | 12,415 (24.15) | 247,485 (17.87) | 13,256 (5.15) | 6926 (17.44) | |
| 50–59 | 311,760 (35.39) | 18,812 (36.59) | 382,098 (27.59) | 30,519 (11.85) | 11,443 (28.82) | |
| 60–69 | 194,836 (22.12) | 11,227 (21.84) | 382,166 (27.59) | 94,576 (36.71) | 9164 (23.08) | |
| ≥ 70 | 71,870 (8.16) | 4064 (7.91) | 286,675 (20.70) | 117,422 (45.58) | 8570 (21.58) | |
| Sex | < 0.0001 | |||||
| Male | 562,581 (63.86) | 36,051 (70.13) | 843,752 (60.92) | 110,849 (43.03) | 25,582 (64.42) | |
| Female | 318,346 (36.14) | 15,355 (29.87) | 541,230 (39.08) | 146,789 (56.97) | 14,127 (35.58) | |
| BMI (kg/m2) | 24.96 ± 3.51 | 25.54 ± 3.98 | 25.13 ± 3.81 | 25.12 ± 3.42 | 24.82 ± 3.37 | < 0.0001 |
| < 18.5 | 16,790 (1.91) | 1,182 (2.30) | 19,663 (1.42) | 4417 (1.71) | 704 (1.77) | |
| 18.5 ≤ < 23 | 235,062 (26.68) | 11,846 (23.04) | 330,474 (23.86) | 61,445 (23.85) | 10,883 (27.41) | |
| 23 ≤ < 25 | 215,368 (24.45) | 11,082 (21.56) | 346,881 (25.05) | 63,275 (24.56) | 10,175 (25.62) | |
| 25 ≤ < 30 | 344,002 (39.05) | 21,002 (40.86) | 583,652 (42.14) | 108,572 (42.14) | 15,248 (38.40) | |
| ≥ 30 | 69,705 (7.91) | 6294 (12.24) | 104,312 (7.53) | 19,929 (7.74) | 2699 (6.80) | |
| Smoking history | < 0.0001 | |||||
| Never smoker | 447,417 (50.79) | 22,913 (44.57) | 770,372 (55.62) | 182,650 (70.89) | 21,030 (52.96) | |
| Ex-smoker | 155,334 (17.63) | 9674 (18.82) | 268,535 (19.39) | 40,583 (15.75) | 9028 (22.74) | |
| Current smoker | 278,176 (31.58) | 18,819 (36.61) | 346,075 (24.99) | 34,405 (13.35) | 9651 (24.30) | |
| Alcohol consumption | < 0.0001 | |||||
| Non-drinker | 442,747 (50.26) | 23,729 (46.16) | 800,702 (57.81) | 198,263 (76.95) | 23,052 (58.05) | |
| Mild drinker | 326,402 (37.05) | 18,628 (36.24) | 452,929 (32.70) | 48,528 (18.84) | 13,422 (33.80) | |
| Heavy drinker | 111,778 (12.69) | 9049 (17.60) | 131,351 (9.48) | 10,847 (4.21) | 3235 (8.15) | |
| Regular physical activity | 176,918 (20.08) | 9580 (18.64) | 290,988 (21.01) | 48,711 (18.91) | 8736 (22.00) | < 0.0001 |
| Income level | < 0.0001 | |||||
| 1st quartile | 190,147 (21.58) | 11,612 (22.59) | 286,580 (20.69) | 54,918 (21.32) | 5927 (14.93) | |
| 2nd quartile | 188,211 (21.37) | 11,428 (22.23) | 254,189 (18.35) | 42,492 (16.49) | 5987 (15.08) | |
| 3rd quartile | 235,985 (26.79) | 13,531 (26.32) | 351,556 (25.38) | 61,222 (23.76) | 9530 (24.00) | |
| 4th quartile | 266,584 (30.26) | 14,835 (28.86) | 492,657 (35.57) | 99,006 (38.43) | 18,265 (46.00) | |
| Comorbidities | ||||||
| Hypertension | 429,176 (48.72) | 32,721 (63.65) | 793,557 (57.30) | 200,840 (77.95) | 24,793 (62.44) | < 0.0001 |
| Dyslipidemia | 332,360 (37.73) | 24,353 (47.37) | 586,012 (42.31) | 136,630 (53.03) | 17,665 (44.49) | < 0.0001 |
| COPD | 66,821 (7.59) | 4070 (7.92) | 130,013 (9.39) | 35,915 (13.94) | 3995 (10.06) | < 0.0001 |
| Cancer | 23,876 (2.71) | 1411 (2.74) | 44,187 (3.19) | 11,247 (4.37) | 1372 (3.46) | < 0.0001 |
| CHF | 1434 (0.16) | 156 (0.30) | 3525 (0.25) | 2268 (0.88) | 457 (1.15) | < 0.0001 |
| Systolic BP (mmHg) | 128.21 ± 15.50 | 133.15 ± 17.47 | 129.16 ± 15.75 | 130.68 ± 16.88 | 130.01 ± 16.8 | < 0.0001 |
| Diastolic BP (mmHg) | 79.17 ± 10.21 | 82.10 ± 11.34 | 79.14 ± 10.25 | 78.20 ± 10.59 | 78.28 ± 10.48 | < 0.0001 |
| Total cholesterol (mg/dL) | 196.54 ± 45.81 | 206.33 ± 54.47 | 198.06 ± 46.77 | 195.25 ± 49.49 | 191.99 ± 47.61 | < 0.0001 |
| HDL-C (mg/dL) | 52.55 ± 33.41 | 51.78 ± 21.34 | 51.75 ± 22.52 | 50.41 ± 24.59 | 69.17 ± 108.30 | < 0.0001 |
| LDL-C (mg/dL) | 111.46 ± 80.82 | 113.81 ± 75.29 | 113.62 ± 87.86 | 111.69 ± 85.67 | 110.23 ± 69.02 | < 0.0001 |
| Dipstick albuminuria ≥ 1 + | 0 (0) | 51,406 (5.51) | 85,435 (6.17) | 34,375 (13.34) | 7659 (19.29) | < 0.0001 |
Data are presented as the mean ± standard deviation, or n(%).
DKD diabetic kidney disease; BMI body mass index; COPD chronic obstructive pulmonary disease; CHF congestive heart failure; BP blood pressure; HDL-C high-density lipoprotein cholesterol; LDL-C low-density lipoprotein cholesterol.
aNo DKD: estimated glomerular filtration rate(eGFR) ≥ 90 mL/min/1.73m2, negative or trace in dipstick proteinuria, bDKD stage 1: eGFR ≥ 90 mL/min/1.73m2, ≥ 1 + in dipstick proteinuria, cDKD stage 2: 60 mL/min/1.73m2 ≤ eGFR < 90 mL/min/1.73m2, dDKD stage 3: 30 mL/min/1.73m2 ≤ eGFR < 60 mL/min/1.73m2, eDKD stage 4: eGFR < 30 mL/min/1.73m2.
Risk of various causes of death according to DKD stage
The major causes of death were neoplasm and circulatory system diseases irrespective of kidney function. The more advanced the stage of DKD was, the higher the incidence rate for mortality with endocrine and metabolic diseases and genitourinary system disorders. For all categories of death except endocrine and metabolic disorders, the highest incidence rate occurred in DKD stage 3. Subjects with DKD stage 1 showed a higher incidence rate of most causes of death except nervous system disorders than subjects with no DKD (Table 2).
Table 2.
Incidence rates of causes of death according to DKD stage.
| aNo DKD (n = 880,927) | bDKD stage 1 (n = 51,406) | cDKD stage 2 (n = 1,384,982) | dDKD stage 3 (n = 257,638) | eDKD stage 4 (n = 39,709) | P-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N | IR (95% CI) | N | IR (95% CI) | N | IR (95% CI) | N | IR (95% CI) | N | IR (95% CI) | ||
| All Cause | 69,476 | 9.00 (8.93–9.07) | 6501 | 14.66 (14.31–15.02) | 159,776 | 13.15 (13.09–13.22) | 66,850 | 31.45 (31.22–31.69) | 8749 | 25.48 (24.95–26.02) | < 0.001 |
| Infectious disease | 1835 | 0.24 (0.23–0.25) | 176 | 0.40 (0.34–0.46) | 4313 | 0.36 (0.35–0.37) | 2091 | 0.98 (0.94–1.03) | 198 | 0.58 (0.50–0.66) | < 0.001 |
| Neoplasm | 25,891 | 3.35 (3.31–3.40) | 2024 | 4.57 (4.37–4.77) | 54,963 | 4.53 (4.49–4.56) | 15,704 | 7.39 (7.27–7.51) | 1587 | 4.62 (4.40–4.85) | < 0.001 |
| Endocrine and metabolic disease | 4487 | 0.58 (0.56–0.60) | 684 | 1.54 (1.43–1.66) | 12,101 | 1.00 (0.98–1.01) | 8507 | 4.00 (3.92–4.09) | 1855 | 5.40 (5.16–5.65) | < 0.001 |
| Nervous system disorders | 1510 | 0.20 (0.19–0.21) | 87 | 0.20 (0.16–0.24) | 4370 | 0.36 (0.35–0.37) | 1877 | 0.88 (0.84–0.92) | 129 | 0.38 (0.32–0.45) | < 0.001 |
| Diseases of the circulatory system | 11,121 | 1.44 (1.41–1.47) | 1204 | 2.72 (2.57–2.87) | 31,597 | 2.60 (2.57–2.63) | 16,452 | 7.74 (7.62–7.86) | 1909 | 5.56 (5.32–5.81) | < 0.001 |
| Diseases of the respiratory system | 5309 | 0.69 (0.67–0.71) | 473 | 1.07 (0.98–1.17) | 15,046 | 1.24 (1.22–1.26) | 6529 | 3.07 (3.00–3.15) | 533 | 1.55 (1.43–1.69) | < 0.001 |
| Diseases of the digestive system | 4664 | 0.60 (0.59–0.62) | 474 | 1.07 (0.98–1.17) | 6361 | 0.52 (0.51–0.54) | 2308 | 1.09 (1.04–1.13) | 305 | 0.89 (0.79–0.99) | < 0.001 |
| Diseases of the genitourinary system | 757 | 0.10 (0.09–0.11) | 189 | 0.43 (0.37–0.49) | 2892 | 0.24 (0.23–0.25) | 3257 | 1.53 (1.48–1.59) | 1166 | 3.40 (3.21–3.60) | < 0.001 |
| Injury from external causes | 8226 | 1.07 (1.04–1.09) | 650 | 1.47 (1.36–1.58) | 14,310 | 1.18 (1.16–1.20) | 3609 | 1.70 (1.64–1.75) | 444 | 1.29 (1.18–1.42) | < 0.001 |
*IR incidence rate per 1000 person-years.
aNo DKD: eGFR ≥ 90 mL/min/1.73m2, negative or trace in dipstick proteinuria, bDKD stage 1: eGFR ≥ 90 mL/min/1.73m2, ≥ 1 + in dipstick proteinuria, cDKD stage 2: 60 mL/min/1.73m2 ≤ eGFR < 90 mL/min/1.73m2, dDKD stage 3: 30 mL/min/1.73m2 ≤ eGFR < 60 mL/min/1.73m2, eDKD stage 4/5: eGFR < 30 mL/min/1.73m2.
In the risk assessment, the advanced stage of DKD showed the highest risk of death from all causes, endocrine and metabolic disorders and circulatory system disorders. The risk of all categories of death was significantly increased among subjects with DKD stage 1 compared with those with DKD stage 2 (Table 3).
Table 3.
Risk of causes of death according to DKD stage.
| Group | Number of patients | Events | HR(95% CI) | ||||
|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | ||||
| All Cause | No DKD | 880,927 | 69,476 | 0.69 (0.68–0.69) | 1.10 (1.09–1.11) | 1.05 (1.04–1.06) | 1.05 (1.04–1.06) |
| DKD stage 1 | 51,406 | 6501 | 1.12(1.09–1.15) | 1.75 (1.70–1.79) | 1.66 (1.62–1.70) | 1.64 (1.60–1.68) | |
| DKD stage 2 | 1,384,982 | 159,776 | 1(Ref.) | 1(Ref.) | 1(Ref.) | 1(Ref.) | |
| DKD Stage 3 | 257,638 | 66,850 | 2.41 (2.39–2.43) | 1.44 (1.42–1.45) | 1.47 (1.45–1.48) | 1.44 (1.43–1.46) | |
| DKD Stage 4 | 39,709 | 8749 | 1.91 (1.87–1.95) | 2.13 (2.08–2.18) | 2.14 (2.10–2.19) | 2.08 (2.03–2.12) | |
| Neoplasm | No DKD | 880,927 | 25,891 | 0.74 (0.73–0.75) | 1.12 (1.10–1.13) | 1.09 (1.07–1.10) | 1.08 (1.06–1.09) |
| DKD stage 1 | 51,406 | 2024 | 1.01 (0.97–1.06) | 1.46 (1.39–1.52) | 1.40 (1.34–1.47) | 1.41 (1.35–1.48) | |
| DKD stage 2 | 1,384,982 | 54,963 | 1(Ref.) | 1(Ref.) | 1(Ref.) | 1(Ref.) | |
| DKD Stage 3 | 257,638 | 15,704 | 1.64 (1.61–1.67) | 1.06 (1.04–1.08) | 1.07 (1.05–1.09) | 1.07 (1.05–1.09) | |
| DKD Stage 4 | 39,709 | 1587 | 1.01 (0.96–1.07) | 1.11 (1.06–1.17) | 1.12 (1.06–1.18) | 1.10 (1.05–1.16) | |
| Endocrine and metabolic disease | No DKD | 880,927 | 4487 | 0.59 (0.57–0.61) | 0.96 (0.93–0.99) | 0.90 (0.87–0.93) | 0.91 (0.88–0.94) |
| DKD stage 1 | 51,406 | 684 | 1.56 (1.44–1.68) | 2.52 (2.33–2.73) | 2.39 (2.22–2.59) | 2.30 (2.13–2.49) | |
| DKD stage 2 | 1,384,982 | 12,101 | 1(Ref.) | 1(Ref.) | 1(Ref.) | 1(Ref.) | |
| DKD Stage 3 | 257,638 | 8507 | 4.05 (3.94–4.17) | 2.31 (2.25–2.38) | 2.39 (2.32–2.45) | 2.28 (2.21–2.34) | |
| DKD Stage 4 | 39,709 | 1855 | 5.37 (5.11–5.64) | 6.01 (5.72–6.31) | 6.01 (5.73–6.31) | 5.69 (5.41–5.97) | |
| Diseases of the circulatory system | No DKD | 880,927 | 11,121 | 0.56 (0.54–0.57) | 0.95 (0.93–0.97) | 0.92 (0.90–0.94) | 0.93 (0.91–0.95) |
| DKD stage 1 | 51,406 | 1204 | 1.05 (0.99–1.11) | 1.79 (1.68–1.89) | 1.72 (1.62–1.82) | 1.64 (1.55–1.74) | |
| DKD stage 2 | 1,384,982 | 31,597 | 1(Ref.) | 1(Ref.) | 1(Ref.) | 1(Ref.) | |
| DKD Stage 3 | 257,638 | 16,452 | 3.00 (2.95–3.06) | 1.65 (1.61–1.68) | 1.67 (1.63–1.70) | 1.58 (1.55–1.62) | |
| DKD Stage 4 | 39,709 | 1909 | 2.11 (2.01–2.21) | 2.37 (2.26–2.48) | 2.38 (2.27–2.49) | 2.22 (2.12–2.33) | |
| Diseases of the respiratory system | No DKD | 880,927 | 5309 | 0.56 (0.54–0.58) | 1.11 (1.08–1.15) | 1.04 (1.00–1.07) | 1.03 (1.00–1.06) |
| DKD stage 1 | 51,406 | 473 | 0.87 (0.79–0.95) | 1.70 (1.55–1.87) | 1.62 (1.48–1.77) | 1.61 (1.47–1.77) | |
| DKD stage 2 | 1,384,982 | 15,046 | 1(Ref.) | 1(Ref.) | 1(Ref.) | 1(Ref.) | |
| DKD Stage 3 | 257,638 | 6529 | 2.52 (2.45–2.60) | 1.26 (1.23–1.30) | 1.31 (1.28–1.35) | 1.30 (1.27–1.34) | |
| DKD Stage 4 | 39,709 | 533 | 1.22 (1.12–1.33) | 1.40 (1.29–1.53) | 1.41 (1.29–1.53) | 1.37 (1.26–1.49) | |
| Diseases of the digestive system | No DKD | 880,927 | 4664 | 1.16 (1.11–1.20) | 1.51 (1.45–1.57) | 1.37 (1.31–1.42) | 1.35 (1.30–1.40) |
| DKD stage 1 | 51,406 | 474 | 2.05 (1.86–2.25) | 2.55 (2.32–2.80) | 2.22 (2.02–2.43) | 2.23 (2.03–2.45) | |
| DKD stage 2 | 1,384,982 | 6361 | 1(Ref.) | 1(Ref.) | 1(Ref.) | 1(Ref.) | |
| DKD Stage 3 | 257,638 | 2308 | 2.08 (1.99–2.18) | 1.56 (1.49–1.64) | 1.64 (1.56–1.72) | 1.65 (1.57–1.73) | |
| DKD Stage 4 | 39,709 | 305 | 1.69 (1.51–1.89) | 1.80 (1.60–2.02) | 1.85 (1.65–2.08) | 1.82 (1.62–2.05) | |
DKD diabetic kidney disease; HR hazard ratio; 95% CI 95% confidence interval.
Model 1 was non-adjusted. Model 2 was adjusted for age and sex. Model 3 was adjusted for variables in model 2 and BMI, smoking history, alcohol consumption and physical activity Model 4 was adjusted for variables in model 3 and comorbidities (hypertension, dyslipidemia, COPD, cancer, and CHF).
Impact of albuminuria on each cause of mortality
Even in the same eGFR group, the risk for mortality due to each cause was higher among the subjects with albuminuria (Fig. 2). In the absence of albuminuria, reduced eGFR progressively increased mortality from all causes, endocrine and metabolic diseases, and circulatory diseases. The presence of albuminuria in addition to reduced eGFR exponentially increased the risk of death in these groups (Fig. 2). Death from endocrine and metabolic diseases, the main causes of mortality, was prominently distinguished according to the presence of albuminuria in DKD stage 3 (adjusted HR [aHR], 5.953; 95% CI, 5.687‒6.232 in nonalbuminuria vs. aHR, 2.087; 95% CI, 2.020‒2.156 in albuminuria) and DKD stage 4 (aHR, 15.731; 95% CI, 14.714‒16.819 in nonalbuminuria vs. aHR, 3.887; 95% CI, 3.630‒4.163 in albuminuria).
Figure 2.
The adjusted risk of mortality from (A) all causes, (B) endocrinology and metabolic diseases, (C) circulatory diseases, (D) neoplasms, (E) respiratory diseases, and (F) digestive diseases according to the stage of diabetic kidney disease. Adjusted variables were age, sex, body mass index, smoking history, alcohol consumption, physical activity and comorbidities such as hypertension, dyslipidemia, chronic obstructive pulmonary disease, cancer, and congestive heart failure. HR hazard ratio; CI confidence interval; DKD diabetic kidney disease.
Although albuminuria in advanced DKD showed a significant impact on the increased risk of mortality from respiratory disease and digestive disease, a reduced eGFR alone did not promote an incrementally increased risk for mortality. Likewise, death from neoplasms was influenced only by the presence of albuminuria, not by reduced eGFR (Fig. 2).
We analyzed the causes of death from the circulatory system in detail. As shown in Supplemental Fig. 1, the risk of death was higher among the subjects with albuminuria than among those without albuminuria in the same stage of DKD. This trend was observed in subcategories of the circulatory system, such as hypertensive disorder, ischemic heart disease, and cerebrovascular disease.
Discussion
WE investigated the impact of the presence of diabetes on each cause of mortality using national health insurance data in South Korea. Diabetes has a significant role in the death of patients with major organ diseases. Moreover, we identified that the presence of albuminuria significantly increased the risk of mortality irrespective of DKD stage. In particular, the presence of albuminuria adds to the reduced eGFR and synergistically increased mortality from all causes, endocrine and metabolic diseases, and circulatory diseases. Considering the different impacts of eGFR and albuminuria on each cause of mortality, these results could be a helpful guide for the focus of disease management.
Diabetes is a metabolic disorder that is characterized by hyperglycemia and glucose intolerance. Many complications begin with the chronic hyperglycemic status, and this is accompanied by high mortality and morbidity due to microvascular and macrovascular complications22. These vascular complications ultimately involve overall major organ diseases, which might increase the risk of mortality irrespective of the site specificity. In this regard, diabetes is associated with not only cardiovascular death but also other substantial premature deaths from cancer, infectious diseases, external causes, and degenerative disorders23,24. We found that these risks of mortality were incrementally increased according to kidney dysfunction among patients with diabetes. In addition, the presence of albuminuria has a more prominent impact on the increased risk of mortality irrespective of the cause of death.
Albuminuria is a significant early sign that indicates kidney damage in diabetes. In addition, it has also been recognized as a powerful risk factor for adverse clinical outcomes in various clinical settings, including cardiovascular disease17,18,25. Even a small increase in albuminuria or detection of albuminuria at a single visit significantly increased the risk of major cerebro-cardiovascular events such as cardiovascular death, ischemic stroke, and myocardial infarction26. In addition to the presence of albuminuria, reduced eGFR is another independent risk factor for cardiovascular and renal outcomes, so these two variables are considered more suitable for risk assessment than other clinical risk factors in diabetic patients14,27. Although there are limited data to represent the association between these factors and adverse outcomes other than cardiovascular outcome, this study showed a difference in the impact of albuminuria and reduced eGFR according to each cause of death.
The impact of diabetes on the development of cardiovascular disease and cardiovascular mortality has been extensively evaluated for decades14,17. Likewise, similar results were obtained in this study. In particular, the synergistic effect of reduced eGFR and the presence of albuminuria was prominent in death due to circulatory diseases in this study. This finding could be related to the strong association between the severity of DKD and cardiovascular disease. Additionally, we found that subcategories of cardiovascular disease such as hypertensive disorders, ischemic heart disease, other heart disease, and cerebrovascular disease also showed a well-discriminated risk of mortality according to the presence of albuminuria and stage of DKD. Thus, additional attention to albuminuria is necessary for high-risk patients with cardiovascular disease.
In addition to cardiovascular mortality, death from endocrine and metabolic diseases also showed a synergistically increased risk of mortality according to the DKD stage and the presence of albuminuria. Diseases of the endocrine system include not only diabetes and thyroid diseases but also malnutrition, electrolyte imbalances, and acid–base disorder, which could be a common cause of death among patients with advanced kidney disease. However, because the death certificate is completed according to the ICD-10 code, this category could include overall death from diabetes, without evaluation for specific causes. Therefore, a more detailed evaluation of the cause of death in diabetic patients needs to be performed using a well-designed prospective cohort study to improve the accuracy of these vague results.
Interestingly, subjects with DKD stage 1 showed a higher risk of mortality than those with DKD stage 3 for all types of death. Moreover, even subjects with no DKD showed a higher risk of all-cause mortality, death from neoplasms, and death due to diseases of the digestive system than those with DKD stage 2. This could be related to the hazard effect of glomerular hyperfiltration as an independent risk factor for all-cause mortality28. Moreover, this relationship was more prominent in diabetic patients, and the risk of mortality in subjects with hyperfiltration was reported to be similar to or even higher than that among subjects with an eGFR < 60 mL/min/1.73 m229. However, in the separate analysis according to the presence of albuminuria, the impact of hyperfiltration was attenuated. The risk with DKD stage 1 was significantly higher than that with DKD stage 2 but not higher than that with DKD stage 3 for most causes of death except neoplasms. Based on the results of this study, we suggest that the presence of albuminuria synergistically increased the hazard effect of hyperfiltration for all types of death.
Among the indicators representing kidney dysfunction, in addition to the eGFR value, the presence of albuminuria, a kidney damage marker, showed a more prominent impact on the risk of mortality irrespective of specific causes. Moreover, these two markers showed different associations according to each cause of death. This significant finding, based on the nationwide population cohort, has not been commonly identified before. However, there were several limitations of this study to be discussed. First, this study is a retrospective cohort study. Second, we used only the ICD-10 code on the death certificate to determine the cause of mortality. This means that the exact clinical situation at the time of death could not be identified. Third, only qualitative results for albuminuria were used for analysis, and quantitative results were not available in this study. Fourth, despite the study targeting diabetic patients, we could not consideration of the severity of diabetes, disease duration, number of medications, usage of insulin, family history, or presence of complications. Lastly, this study was conducted based on the large database, it could be related to the smaller P value and a higher likelihood of rejecting the null hypothesis. In this regard, we additionally provided 95% CI as a measure to let the readers evaluate the significance of the findings.
The mortality risk among patients with DM was incrementally increased according to the stage of DKD regardless of the cause of death. In addition to kidney function, the impact of albuminuria on mortality was prominent in all stages of DKD. Even for patients with a favorable eGFR, the presence of albuminuria should be considered a significant marker for mortality.
Materials and methods
Ethical considerations
This study complied with the Declaration of Helsinki. The institutional review board of Seoul National University Hospital (E-2107-186-1237) approved this study. The attending government organization approved using the data from the National Health Insurance Service (NHIS) (No. NHIS-2021-1-592). The subject data were anonymized and deidentified for the analysis, so the requirement for informed consent was waived.
Study population and data collection
We extracted subjects with diabetes from the subjects who underwent national health examinations from January 2009 to December 2012. Diabetic patients were identified by the following clinical criteria: (1) fasting plasma glucose ≥ 126 mg/dl at the national health examination and (2) the presence of a claim for the diagnostic codes E11, E12, E13, and E14 based on the 10th International Classification of Diseases (ICD-10) code and the prescription of oral hypoglycemic agents or insulin for diabetes at the same time.
The exclusion criteria were as follows: (1) age < 20 years old, (2) previous treatment with hemodialysis, peritoneal dialysis, or kidney transplantation. The subjects were followed up until December 2019.
Data collection
All the data were obtained from the National Health Insurance Database of South Korea operated by NHIS. We collected the demographic characteristics, including age, sex, smoking history, alcohol consumption, physical activity, and income level. In addition, we obtained anthropometric data, including body mass index (BMI) and systolic and diastolic blood pressure, which were measured at the time of the routine health examination. Major comorbidities, including hypertension, dyslipidemia, chronic obstructive pulmonary disease, cancer, and congestive heart failure, were also investigated based on the ICD-10 codes. We obtained laboratory results, including serum creatinine, albuminuria, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol.
Definition of DKD stages
The definition and stage of DKD were based on the Kidney Disease: Improving Global Outcomes CKD guideline30. The estimated GFR (eGFR) was calculated by the Modification of Diet in Renal Disease equation, and the presence of albuminuria was defined as dipstick urine albumin ≥ 1 + . The stage of DKD was categorized according to the following criteria: (1) no DKD; eGFR ≥ 90 mL/min/1.73 m2 and absence of albuminuria, (2) DKD stage 1; eGFR ≥ 90 mL/min/1.73 m2 and presence of albuminuria, (3) DKD stage 2; 60 ≤ eGFR < 90 mL/min/1.73 m2, (4) DKD stage 3; 30 ≤ eGFR < 60 mL/min/1.73 m2, (5) DKD stage 4; eGFR < 30 mL/min/1.73 m2. To evaluate the clinical significance of albuminuria in DKD patients, we further categorized the subgroups according to albuminuria in each stage of DKD. The presence of albuminuria was defined as 1 + and above in dipstick urinalysis.
Study outcomes
The impact of diabetes on each cause of mortality according to the stage of DKD was set as a primary outcome. In addition, we evaluated the impact of albuminuria on each cause of mortality in each stage of DKD. The causes of death were classified into 9 groups according to the ICD-10 code on the death certificate: (1) infectious disease, (2) neoplasm, (3) endocrine and metabolic diseases, (4) nervous system disorders, (5) diseases of the circulatory system, (6) diseases of the respiratory system, (7) diseases of the digestive system, (8) diseases of the genitourinary system, and (9) injury from external causes. We excluded the categories with a very low number of deaths, such as diseases of the eye and adnexa; ear and mastoid process diseases; pregnancy, childbirth and the puerperium; and congenital malformation, deformations, and chromosomal abnormalities, from the analysis.
We additionally evaluated the specific cause of death of subjects with circulatory system disease codes. The detailed causes of death were classified based on the ICD-10 code in detail: (1) hypertensive disorder, (2) ischemic heart disease, (3) other cardiac diseases, (4) cerebrovascular disease, and (5) atherosclerosis.
Statistical analysis
Continuous variables are presented as the mean ± standard deviation, and categorical variables are presented as percentages. To compare the groups, we performed ANOVA or the chi-square test. Two-sided P values were derived by setting the significance level at 0.05. The incidence rate of outcome was demonstrated as per 1000 person-years. For the risk assessment of each cause of death, we selected clinically important and frequent categories for further analysis to determine the significance of albuminuria on mortality: (1) all-cause death, (2) cancer, (3) endocrine and metabolic disease, (4) circulatory system disorders, (5) respiratory system disorders, and (6) digestive system disorders. Cox proportional hazards regression models were used to evaluate the risk of mortality. We adjusted for the following variables: age, sex, BMI, smoking status, drinking status, physical activity, history of comorbidities: hypertension, dyslipidemia, congestive heart failure, chronic obstructive lung disease, and cancer in the multivariate models. The SAS 9.4 program (SAS Institute, Cary, NC, USA) was used to perform statistical analysis.
Supplementary Information
Author contributions
Participated in research design: S.C., S.P., S.J., K.H., Y.K., D.K.K. Participated in the collection of the data: S.C., K.L., K.H., Y.K. Participated in the data analysis: K.L., K.H. Participated in the writing of the paper: S.C., S.P., S.J., K.H., Y.K., D.K.K. Participated in editing and revising the manuscript: S.C., H.H., S.P., S.L., S.J., M.K., K.L., J.H.P., W.Y.P., K.J., S.H., K.W.J., C.S.L., Y.S.K., K.H., Y.K., D.K.K.
Funding
This research was supported by the Young Investigator Research Grant from the KOREAN NEPHROLOGY RESEARCH FOUNDATION (2021). The funding source had no involvement in the study design; data collection, analysis and interpretation of data; writing of the report; and the decision to submit the article for publication.
Data availability
The datasets generated and/or analyzed in the current study are available from the corresponding author on reasonable request.
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Kyungdo Han, Email: hkd917@naver.com.
Yaerim Kim, Email: yaerim86@gmail.com.
Supplementary Information
The online version contains supplementary material available at 10.1038/s41598-022-23352-0.
References
- 1.Collaborators GDaIIaP Global regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the global burden of disease study 2015. Lancet. 2016;388:1545–1602. doi: 10.1016/S0140-6736(16)31678-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Federation, I. D. IDF Diabetes Atlas, 8th edn (International Diabetes Federation, Brussels, Belgium, 2017).
- 3.Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the international diabetes federation diabetes atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. [DOI] [PubMed] [Google Scholar]
- 4.Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017;389:2239–2251. doi: 10.1016/S0140-6736(17)30058-2. [DOI] [PubMed] [Google Scholar]
- 5.Rask-Madsen C, King GL. Vascular complications of diabetes: Mechanisms of injury and protective factors. Cell Metab. 2013;17:20–33. doi: 10.1016/j.cmet.2012.11.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Fact sheet: Diabetes [Internet]. World Health Organization. (2021).
- 7.Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M. Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: Comparative risk assessment. Lancet. 2006;368:1651–1659. doi: 10.1016/S0140-6736(06)69700-6. [DOI] [PubMed] [Google Scholar]
- 8.Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–2222. doi: 10.1016/S0140-6736(10)60484-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339:229–234. doi: 10.1056/NEJM199807233390404. [DOI] [PubMed] [Google Scholar]
- 10.Kim MH, Oh HJ, Kwon SH, Jeon JS, Noh H, Han DC, et al. Metformin use and cardiovascular outcomes in patients with diabetes and chronic kidney disease: A nationwide cohort study. Kidney Res. Clin. Pract. 2021;40:660–672. doi: 10.23876/j.krcp.20.222. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Albai O, Frandes M, Timar B, Paun DL, Roman D, Timar R. Long-term risk of malignant neoplastic disorders in type 2 diabetes mellitus patients with metabolic syndrome. Diabetes Metab. Syndr. Obes. 2020;13:1317–1326. doi: 10.2147/DMSO.S243263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Cantú-Brito C, Mimenza-Alvarado A, Sánchez-Hernández JJ. Diabetes mellitus and aging as a risk factor for cerebral vascular disease: Epidemiology, pathophysiology and prevention. Rev. Invest. Clin. 2010;62:333–342. [PubMed] [Google Scholar]
- 13.Chatterjee S, Mudher A. Alzheimer’s disease and type 2 diabetes: A critical assessment of the shared pathological traits. Front. Neurosci. 2018;12:383. doi: 10.3389/fnins.2018.00383. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 2009;20:1813–1821. doi: 10.1681/ASN.2008121270. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.SystemUSRDS USRD: 2020 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, (2020).
- 16.Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clin. J. Am. Soc. Nephrol. 2017;12:2032–2045. doi: 10.2215/CJN.11491116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426. doi: 10.1001/jama.286.4.421. [DOI] [PubMed] [Google Scholar]
- 18.Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–1782. doi: 10.1161/01.CIR.0000031732.78052.81. [DOI] [PubMed] [Google Scholar]
- 19.Oelsner EC, Balte PP, Grams ME, Cassano PA, Jacobs DR, Barr RG, et al. Albuminuria, lung function decline, and risk of incident chronic obstructive pulmonary disease. The NHLBI pooled cohorts study. Am. J. Respir. Crit. Care Med. 2019;199:321–332. doi: 10.1164/rccm.201803-0402OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Park S, Lee HJ, Han KD, Soh H, Moon JM, Hong SW, et al. Proteinuria is associated with the development of Crohn’s disease: A nationwide population-based study. J. Clin. Med. 2021;10:799. doi: 10.3390/jcm10040799. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Cho EB, Shin HY, Park SE, Chun P, Jang HR, Yang JJ, et al. Albuminuria, cerebrovascular disease and cortical atrophy: Among cognitively normal elderly individuals. Sci. Rep. 2016;6:20692. doi: 10.1038/srep20692. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ohiagu FO, Chikezie PC, Chikezie CM. Pathophysiology of diabetes mellitus complications: Metabolic events and control. Biomed. Res. Ther. 2021;8:4243–4257. doi: 10.15419/bmrat.v8i3.663. [DOI] [Google Scholar]
- 23.Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011;364:829–841. doi: 10.1056/NEJMoa1008862. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Charytan DM, Lewis EF, Desai AS, Weinrauch LA, Ivanovich P, Toto RD, et al. Cause of death in patients with diabetic CKD enrolled in the trial to reduce cardiovascular events with aranesp therapy (TREAT) Am. J. Kidney Dis. 2015;66:429–440. doi: 10.1053/j.ajkd.2015.02.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, et al. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 2013;24:302–308. doi: 10.1681/ASN.2012070718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, et al. Cardiovascular outcomes according to urinary albumin and kidney disease in patients with type 2 diabetes at high cardiovascular risk: Observations from the SAVOR-TIMI 53 trial. JAMA Cardiol. 2018;3:155–163. doi: 10.1001/jamacardio.2017.4228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Tong L-L, Adler SG. Diabetic kidney disease treatment: New perspectives. Kidney Res. Clin. Pract. 2022;41:S63–S73. doi: 10.23876/j.krcp.21.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Park M, Yoon E, Lim YH, Kim H, Choi J, Yoon HJ. Renal hyperfiltration as a novel marker of all-cause mortality. J. Am. Soc. Nephrol. 2015;26:1426–1433. doi: 10.1681/ASN.2014010115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Penno G, Orsi E, Solini A, Bonora E, Fondelli C, Trevisan R, et al. Renal hyperfiltration is independently associated with increased all-cause mortality in individuals with type 2 diabetes: A prospective cohort study. BMJ Open Diabetes Res. Care. 2020;8:e001481. doi: 10.1136/bmjdrc-2020-001481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.KDIGO CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. Suppl. 2013;3:1–150. doi: 10.1038/ki.2013.243. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets generated and/or analyzed in the current study are available from the corresponding author on reasonable request.